시장보고서
상품코드
1152253

세계의 애완동물용 암 치료제 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 치료법별, 동물 유형별, 암 유형별, 기업별, 지역별(2017-2027년)

Pet Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Therapy, By Animal Type, By Cancer Type, By Company, and By Region

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 114 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 애완동물용 암 치료제 시장 규모는 예측기간 중 2023-2027년에 눈부신 성장을 이룰 것으로 예측되고 있습니다.

시장 성장의 주요 요인은 애완 동물의 건강에 대한 의식 증가와 동물의 암 발병률 증가입니다. 또, 시장 성장을 지지하는 기타의 요인으로서, 애완동물의 소유율·동물 사육수의 확대, 진단 기술의 진보, 연구 개발 이니셔티브의 증대 등을 들 수 있습니다. 게다가 애완동물의 온콜로지 치료 및 관리와 관련된 R&D 활동에 대한 많은 투자가 앞으로 수년간 시장 기업들에게 유리한 기회를 제공할 전망입니다.

세계의 애완동물용 암 치료제(Pet Cancer Therapeutics) 시장에 대해 조사 분석했으며, 부문별·지역별 시장 규모/점유율 예측/시장 역학/기업 개요 등 체계적인 정보를 제공하고 있습니다.

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계 애완동물용 암 치료제 시장에 미치는 영향

제5장 VOC(고객의 목소리)

제6장 세계의 애완동물용 암 치료제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 치료법별(수술, 방사선요법, 화학요법, 면역요법, 기타)
    • 동물 유형별(개, 고양이, 기타)
    • 암 유형별(림프종, 비만세포암, 유선·편평상피암, 기타)
    • 기업별(2021년)
    • 지역별
  • 시장 맵

제7장 북미의 애완동물용 암 치료제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 치료법별
    • 동물 유형별
    • 암 유형별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제8장 유럽의 애완동물용 암 치료제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 치료법별
    • 동물 유형별
    • 암 유형별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 스페인

제9장 아시아 태평양의 애완동물암 치료시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 치료법별
    • 동물 유형별
    • 암 유형별
    • 국가별
  • 아시아 태평양 : 국가별 분석
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주

제10장 남미의 애완동물용 암 치료제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 치료법별
    • 동물 유형별
    • 암 유형별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제11장 중동·아프리카의 애완동물용 암 치료제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 치료법별
    • 동물 유형별
    • 암 유형별
    • 국가별
  • MEA : 국가별 분석
    • 남아프리카
    • 사우디 아라비아
    • 아랍 에미리트 연방
    • 이집트
    • 터키

제12장 시장 역학

  • 촉진 요인
  • 과제

제13장 시장 동향과 개발

제14장 경쟁 상황

  • CH Boehringer Sohn Ko. KG
  • ELIAS Animal Health, LLC
  • Zoetis Inc.
  • AB Science SA
  • Karyopharm Therapeutics, Inc.
  • Vivesto AB
  • Merial Inc.
  • Elanco Animal Health, Inc.
  • Dechra Pharmaceuticals PLC(Anivive Lifesciences)
  • Torigen Pharmaceuticals Inc.

제15장 전략적 제안

LYJ 22.11.24

The global pet cancer therapeutics market is anticipated to observe an impressive growth during the forecast period, 2023-2027. The major factors include growing consciousness of pet's health and increasing incidences of cancer among animals. Cancer in pets is one of the primary reasons for death, globally. Nowadays, pets have better chances to get diagnosed with cancer due which early adoption of treatment plans are required, which bolster the growth of the market. The other factors supporting the market's growth are rise in pet ownership or animal adoption, advancement in diagnostic techniques and rise in R&D initiatives. Additionally, heavy investments in research and development activities coupled with oncology treatment and management in pets offers lucrative opportunities to the market players in upcoming years.

Increasing Awareness regarding Pet Healthcare and Treatments

The increasing domestication of animals and growing concerns regarding pet health among the people are supporting the market growth. In 2021, number of pet dogs owned worldwide was 471 million. People are becoming more thoughtful about their pet's health and are expending generously on the best available animal therapeutics. Average American yearly spending on pet dogs is estimated to be USD 1201. In addition, growing pet's health awareness programs is augmenting the growth of the market. For instance, the Blue Buffalo Foundation and the Pet Cancer Awareness Program (PCA) are some initiatives which raise awareness and provide information to the pet parents.

Increasing Prevalence of Cancer

The growing prevalence of cancer among pet animals, is a contributing factor for the growth of the market. Cancer is one of the key causes of death in pets, mostly in dogs that are older than 10 years. According to the Veterinary Cancer Society, in 2017, cancer was the foremost cause of death in 47% of dogs, especially those that are over the age of 10, and 32% of cats. Leukemia and lymphoma are very common cancer in cats and certain breeds of elderly dogs. In 2017, Animal Cancer Foundation published a study, which revealed approximately around 25% of all dogs will develop a tumor at some point in their life.

Technological Advancements

Various technological advancements, such as the development of highly targeted and specific cures for animal cancer treatment with minimal side effects, are also supporting the market growth. Increasing R&D initiatives for cancer management is propelling the market growth, as various anti-cancer therapies are launching for veterinary cancer treatment. For instance, in 2017, Jackson Laboratory launched Tallwood Canine Cancer Research Initiative (TCCRI), to generate a biobank of dog tumors for giving insights on cancer cure through research. Also, organizations such as Animal Cancer Foundation, Veterinary Cancer Society, Petco Foundation and PetCure Oncology are doing oncology research such as canine cancer genome project to gain the knowledge related to the genetic makeup of cancer tumors in animals. The foremost focus is on the development of anticancer drugs and improvising their effectiveness and reducing their toxic effects on the pet's body.

Market Segmentation

The global pet cancer therapeutics market is segmented into therapy, animal type, cancer type, and company. Based on therapy, the market is divided into surgery, radiotherapy, chemotherapy, immunotherapy, and others. Based on animal type, the market is divided into canine, feline, and others. Based on cancer type, the market is segmented into lymphoma, mast cell cancer, mammary & squamous cell cancer, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising domestication and rise in the occurrence of pet cancers in the country.

Market Players

C.H. Boehringer Sohn Ko. KG, ELIAS Animal Health, LLC, Zoetis Inc., AB Science S.A., Karyopharm Therapeutics, Inc., Vivesto AB, Merial Inc., Elanco Animal Health, Inc., Dechra Pharmaceuticals PLC (Anivive Lifesciences), and Torigen Pharmaceuticals Inc. are some of the leading companies operating in the market.

Report Scope:

In this report, global pet cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Pet Cancer Therapeutics Market, By Therapy:

  • Surgery
  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  • Others

Pet Cancer Therapeutics Market, By Animal Type:

  • Canine
  • Feline
  • Others

Pet Cancer Therapeutics Market, By Cancer Type:

  • Lymphoma
  • Mast Cell Cancer
  • Mammary & Squamous Cell Cancer
  • Others

Pet Cancer Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Pet Cancer Therapeutics Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Pet Cancer Therapeutics Market

5. Voice of Customer

6. Global Pet Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy (Surgery, Radiotherapy, Chemotherapy, Immunotherapy, Others)
    • 6.2.2. By Animal Type (Canine, Feline, Others)
    • 6.2.3. By Cancer Type (Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer, Others)
    • 6.2.4. By Company (2021)
    • 6.2.5. By Region
  • 6.3. Market Map

7. North America Pet Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Animal Type
    • 7.2.3. By Cancer Type
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Pet Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Animal Type
        • 7.3.1.2.3. By Cancer Type
    • 7.3.2. Mexico Pet Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Animal Type
        • 7.3.2.2.3. By Cancer Type
    • 7.3.3. Canada Pet Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Animal Type
        • 7.3.3.2.3. By Cancer Type

8. Europe Pet Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Animal Type
    • 8.2.3. By Cancer Type
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Pet Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Animal Type
        • 8.3.1.2.3. By Cancer Type
    • 8.3.2. Germany Pet Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Animal Type
        • 8.3.2.2.3. By Cancer Type
    • 8.3.3. United Kingdom Pet Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Animal Type
        • 8.3.3.2.3. By Cancer Type
    • 8.3.4. Italy Pet Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By Animal Type
        • 8.3.4.2.3. By Cancer Type
    • 8.3.5. Spain Pet Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By Animal Type
        • 8.3.5.2.3. By Cancer Type

9. Asia-Pacific Pet Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Animal Type
    • 9.2.3. By Cancer Type
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Pet Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Animal Type
        • 9.3.1.2.3. By Cancer Type
    • 9.3.2. India Pet Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Animal Type
        • 9.3.2.2.3. By Cancer Type
    • 9.3.3. Japan Pet Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Animal Type
        • 9.3.3.2.3. By Cancer Type
    • 9.3.4. South Korea Pet Cancer Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapy
        • 9.3.4.2.2. By Animal Type
        • 9.3.4.2.3. By Cancer Type
    • 9.3.5. Australia Pet Cancer Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapy
        • 9.3.5.2.2. By Animal Type
        • 9.3.5.2.3. By Cancer Type

10. South America Pet Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Animal Type
    • 10.2.3. By Cancer Type
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pet Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Animal Type
        • 10.3.1.2.3. By Cancer Type
    • 10.3.2. Argentina Pet Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Animal Type
        • 10.3.2.2.3. By Cancer Type
    • 10.3.3. Colombia Pet Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Animal Type
        • 10.3.3.2.3. By Cancer Type

11. Middle East and Africa Pet Cancer Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapy
    • 11.2.2. By Animal Type
    • 11.2.3. By Cancer Type
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Pet Cancer Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapy
        • 11.3.1.2.2. By Animal Type
        • 11.3.1.2.3. By Cancer Type
    • 11.3.2. Saudi Arabia Pet Cancer Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapy
        • 11.3.2.2.2. By Animal Type
        • 11.3.2.2.3. By Cancer Type
    • 11.3.3. UAE Pet Cancer Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapy
        • 11.3.3.2.2. By Animal Type
        • 11.3.3.2.3. By Cancer Type
    • 11.3.4. Egypt Pet Cancer Therapeutics Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Therapy
        • 11.3.4.2.2. By Animal Type
        • 11.3.4.2.3. By Cancer Type
    • 11.3.5. Turkey Pet Cancer Therapeutics Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Therapy
        • 11.3.5.2.2. By Animal Type
        • 11.3.5.2.3. By Cancer Type

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. C.H. Boehringer Sohn Ko. KG
  • 14.2. ELIAS Animal Health, LLC
  • 14.3. Zoetis Inc.
  • 14.4. AB Science S.A.
  • 14.5. Karyopharm Therapeutics, Inc.
  • 14.6. Vivesto AB
  • 14.7. Merial Inc.
  • 14.8. Elanco Animal Health, Inc.
  • 14.9. Dechra Pharmaceuticals PLC (Anivive Lifesciences)
  • 14.10. Torigen Pharmaceuticals Inc.

15. Strategic Recommendations

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제